
Thermosome Receives U.S. Orphan Drug Designation for Lead Compound THE001, Expands Patent Estate
ODD granted for the treatment of soft tissue sarcomas (STS) Thermosome adds 4 patents to its growing patent estate Munich, Germany – May 12, 2025 – Thermosome, a drug development company focused on targeted tumor therapies, today announced that its lead …